CopyMark Law Group
4.9/5
Drawing for ADVANTX

USPTO serial 97340336

ADVANTX

Reviewed by CopyMark Law Group

Reg. 7239136Status 700Registered
Filing date
Status date
Registration date
Dec 12, 2023
Examiner
LATTUCA, FRANK J
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ADVANTX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kumiko Ide

Kumiko Ide WENDEROTH, LIND & PONACK, L.L.P.1025 CONNECTICUT AVENUE NW, SUITE 500WASHINGTON, DC 20036UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products and preparations for the treatment of neurological disorders and cancer; biological reagents for medical use; pharmaceutical chemical preparations for the treatment of neurological disorders and cancer biopharmaceuticals for the treatment of cancer; pharmaceutical and biological products for the treatment of cancer; pharmaceutical and biological preparations for the treatment of diseases of the central nervous systemACTIVE—
042Scientific research; industrial research in the field of pharmaceutical research and development of drugs and treatments for neurological disorders and cancer; scientific research in biology and chemistry; development of pharmaceutical preparations and drugs; development of pharmaceuticals; Medical and scientific research, namely, conducting clinical trials of pharmaceuticals for others; scientific research in the field of pharmacy; research and development in the pharmaceutical and biotechnology fields; drug discovery services; medical research services; scientific computer programmingACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 12, 2023NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Dec 12, 2023R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 26, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 26, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 6, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 21, 2023FIXDELECTRONIC RECORD REVIEW COMPLETE—
Aug 18, 2023ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Aug 13, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 7, 2023GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Aug 7, 2023GNSIINQUIRY TO SUSPENSION E-MAILED—
Aug 7, 2023CNSISUSPENSION INQUIRY WRITTEN—
Aug 3, 2023RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jul 14, 2023ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jan 19, 2023GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jan 19, 2023GNSLLETTER OF SUSPENSION E-MAILED—
Jan 19, 2023CNSLSUSPENSION LETTER WRITTEN—
Jan 18, 2023DOCKASSIGNED TO EXAMINER—
Apr 5, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 4, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance